Clinical trial
A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
NCT00390936 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00390936 |
|---|---|
| Title | A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors |
| Official title | Phase I Multiple Ascending Dose Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Japanese Patients With Advanced or Metastatic Solid Tumors |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumors |
| Intervention type | Drug |
| Interventions | Brivanib |
| Enrollment | 13 |
| Start date | Oct 1, 2007 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Oct 23, 2006 |
| Last update posted | Jan 25, 2011 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: